//Red Leaf Medical Enters the Urinary Tract Infection Market Secures exclusive rights to market UROMUNE® in Canada

Red Leaf Medical Enters the Urinary Tract Infection Market Secures exclusive rights to market UROMUNE® in Canada

Mississauga, Canada (October 18, 2017) Red Leaf Medical Inc. is pleased to announce that it has signed an exclusive Canadian distribution agreement with Inmunotek, a leading pharmaceutical company based in Spain, to commercialize UROMUNE®, a novel sublingual vaccine for the treatment of recurrent urinary tract infection.

Urinary tract infections (UTIs) are one of the most common infections worldwide. Despite treating the initial infection, recurrence occurs in up to 60 per cent of patients during the first year. Patients suffering from repeated UTIs often rely on continuous and prolonged courses of antibiotics. With the alarming rise of antibiotic resistance worldwide, and with the World Health Organization initiating a Global Action Plan to combat antibiotic resistance, there is an urgent need to find viable alternatives.

“Red Leaf Medical’s deep knowledge of the urology market will enable a successful launch of UROMUNE®,” said Charles Ko, Chief Executive Officer, Red Leaf Medical. “We are delighted to have this opportunity to bring an innovative and much needed solution for recurrent urinary tract infections to patients in Canada.”

UROMUNE® is currently in phase III development with several clinical trials demonstrating success. One study recently published in the International Urogynecology Journal* observed 339 patients with recurrent UTIs on a six–month antibiotic prophylaxis, compared with 360 patients taking UROMUNE® for three months; the study showed that all patients with antibiotic prophylaxis experienced a new UTI during the 12 month follow up phase while only 9.7% of patients taking UROMUNE® experienced a UTI in the same period. A large international multi-centre Randomized Control Trial is currently underway. “We are excited to bring UROMUNE to Canada,” said Dr. Jose Luis Subiza, Chief Executive Officer, Immunotek. “Red Leaf Medical’s track record of success launching new products and their extensive expertise in the field of urology make them an ideal partner.”

About Inmunotek
Inmunotek is a pharmaceutical company based in Madrid, Spain, that researches, develops, manufactures and markets products for the diagnosis and treatment of diseases in the field of allergy and immunology.

Inmunotek is listed on the 2017 FT 1000 – Financial Times listing of Europe’s fastest growing companies.

About Red Leaf Medical Inc.

Red Leaf Medical is the only Canadian healthcare company focused exclusively on providing innovative products and services to the urology market. The company’s portfolio includes products in uro-oncology, endo-urology, male and female incontinence, pediatric urology and infertility. Dynamic and rapidly growing, Red Leaf Medical was ranked as one of Canada’s fastest growing companies in Canadian Business magazine’s PROFIT 500 listing in 2015, 2016 and 2017. Find out more at redleafmedical.com.
*Lorenzo-Gomez et al., Int Urogynecol J. 2013 Jan; 24(1): 127–134.

By |2017-10-19T12:31:35+00:00October 19th, 2017|news|